文献速递老年与多病共存慢病管理

降压试验代表性分析:严重不良事件报告不足

Representativeness of antihypertensive trials: analysis of serious adverse events.
PubMed 文献 · Ann Fam Med · 2022-04-01

该观察性研究比较了110项RAAS降压试验(11项老年人试验平均73岁,99项标准试验平均56岁)与英国社区56,036例服用RAAS药物高血压患者(平均60岁)的严重不良事件(SAE)及住院/死亡发生率。老年人试验SAE率高于标准试验(0.18 vs 0.11事件/人/年,调整IRR 1.74,95%CI 1.03-2.92),但社区住院/死亡率为标准试验SAE率的3.70倍(95%CI 3.12-4.55)、老年人试验的4.35倍(95%CI 2.56-7.69)。结论提示试验报告的SAE远低于社区预期,SAE率或可用于评估试验代表性,临床应用于老年人时需谨慎。

要点

  • 老年人降压试验SAE率高于标准试验,但两者均远低于社区实际住院/死亡 rate。
  • 社区服药者住院/死亡率为标准试验SAE率的3.70倍,老年人试验的4.35倍。
  • SAE率可作为评估降压试验代表性的指标,将试验推荐用于老年人需谨慎。

核心结论

  • 降压试验报告的SAE显著少于社区同年龄段接受等效治疗者的实际住院和死亡事件,SAE率或可评估试验代表性。

研究设计与样本

  • 观察性研究,比较110项RAAS降压试验(11项老年人试验平均73岁,99项标准试验平均56岁)与英国社区56,036例服用RAAS药物的高血压患者(平均60岁)。

主要发现

  • 老年人试验SAE率为0.18事件/人/年,高于标准试验的0.11事件/人/年(调整IRR 1.74,95%CI 1.03-2.92)。
  • 社区住院/死亡率为标准试验SAE率的3.70倍(95%CI 3.12-4.55),为老年人试验SAE率的4.35倍(95%CI 2.56-7.69),均经年龄和性别调整。

关键数值与推荐

  • 老年人试验SAE率0.18事件/人/年,标准试验0.11事件/人/年,调整IRR 1.74(95%CI 1.03-2.92)。
  • 社区住院/死亡率与标准试验SAE率比为3.70(95%CI 3.12-4.55),与老年人试验SAE率比为4.35(95%CI 2.56-7.69)。

临床怎么用

  • 临床将降压试验推荐用于老年人时需谨慎,即使试验专门针对老年人,也应考虑试验SAE报告可能低估社区实际风险。

局限性

  • 研究为观察性设计,试验与社区人群的SAE定义和采集方式可能存在差异;社区数据仅来自英国威尔士,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Context: Representativeness of 'standard' antihypertensive drug trials is uncertain, with limited recruitment of older people. Some trials specifically recruit older participants to address this. Trials are obliged to report hospitalizations and deaths, regardless of cause, as Serious Adverse Events (SAEs). If older-people's trials are representative, we would expect rates of SAEs in trials to be similar to the rate of hospitalisation and death in the community, and higher than standard trials. Objective: To compare the rate of SAEs in hypertension trials to rates of hospitalisation and death among people taking similar treatments in the community. Study Design: Observational study comparing trial populations to a community cohort. Dataset: We identified trials of Renin-Angiotensin-Aldosterone system (RAAS) drugs for hypertension from clinicatrials.gov. We identified a community comparison population of people with hypertension starting RAAS drugs using primary care data from the Wales, UK (SAIL databank). Population studied: Trial participants from 110 RAAS hypertension trials (11 older-people's trials, mean age 73, and 99 standard trials, mean age 56). Community cohort of people with hypertension (n=56,036, mean age 60) starting RAAS drugs. Outcomes: SAEs in trials (mostly accounted for by hospitalizations or deaths) and all-cause hospitalizations/deaths in the community comparison. SAE rates in older-people and standard trials were compared, adjusting for trial characteristics. The community rate was used to calculate the expected rate of hospitalizations/deaths given the age/sex distribution of each trial. We then compared the expected rate with the observed rate of SAEs in each trial. Results: Older-people's trials had higher SAEs rate than standard trials (0.18 versus 0.11 events/person/year, adjusted IRR 1.74, 95% CI 1.03-2.92). The hospitalisation and death rate in the community for those taking RAAS antihypertensives was much greater than the rate of SAEs reported in standard (ratio 3.70 (3.12-4.55)) and older-people's trials (4.35 (2.56-7.69)), adjusting for age and sex. Conclusion: Trials report substantially fewer SAEs than expected from rates of hospitalisations and deaths among similar-aged people receiving equivalent treatments in the community. SAE rates may be a useful metric to assess trial representativeness. Clinicians should be cautious when applying trial recommendations to older people, even when trials focus on older people.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Hanlon P, Shah A, Mair F, et al. Representativeness of antihypertensive trials: analysis of serious adverse events. Ann Fam Med. 2022. PMID: 36944050. doi:10.1370/afm.20.s1.2586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。